How CJC-1295 No-DAC Affects Fasting Insulin and HOMA-IR

Fasting insulin and HOMA-IR (homeostatic model assessment of insulin resistance) are calculated from fasting glucose and fasting insulin. Both markers reflect the degree of peripheral and hepatic insulin resistance: higher insulin at a given glucose concentration means more resistance to insulin's effects.

CJC-1295 no-DAC's short half-life (approximately 30 minutes in plasma) produces discrete GH pulses rather than sustained GH elevation. The key consequence for insulin metabolism:

1. Intermittent vs. sustained GH signalling: GH's anti-insulin effects operate through FFA release (Randle cycle interference) and direct suppression of IRS-1 signalling in muscle and adipose tissue. When GH returns to baseline between pulses, these pathways normalise. Sustained GH elevation (as with MK-677 or high-dose exogenous GH) maintains continuous anti-insulin pressure, which forces compensatory hyperinsulinemia and raises fasting insulin.
2. Hepatic glucose output: GH stimulates hepatic gluconeogenesis acutely. Between CJC-1295 no-DAC pulses, hepatic glucose output returns to basal state, maintaining normal fasting hepatic insulin sensitivity. This is the mechanism by which pulsatile GHRH analogs avoid the HOMA-IR deterioration seen with continuous GH stimulation.
3. Tesamorelin evidence: Falutz et al. (2010, PMID 20554713) measured fasting insulin and glucose across 806 patients randomised to daily tesamorelin 2 mg versus placebo for 26 to 52 weeks. No statistically significant change in fasting insulin or HOMA-IR was observed. Tesamorelin is the best available clinical benchmark for daily GHRH-analog metabolic effects, providing direct evidence that pulsatile GHRH stimulation does not impair insulin sensitivity at therapeutic doses.
4. Contrast with MK-677: Nass et al. (2008, PMID 18981485) documented a 0.3 mmol/L fasting glucose rise and a 0.2% HbA1c increase with MK-677 over 2 years, with rising fasting insulin indicating compensatory hyperinsulinemia. The mechanistic difference is the duration of GH elevation: 24 hours with MK-677 versus 2 to 3 hours per pulse with CJC-1295 no-DAC.

Standard combined protocol (100 mcg CJC-1295 no-DAC + 200-300 mcg ipamorelin, 1-2 times daily):

• Fasting insulin: no clinically significant change expected
• HOMA-IR: no clinically significant change expected based on tesamorelin Phase 3 data
• Fasting glucose: unchanged or minimally changed (see cjc-1295-no-dac-glucose entry)

Post-injection insulin dynamics (not reflected in fasting measurements):

• Following a GH pulse, pancreatic beta-cells secrete more insulin to counter the transient anti-insulin GH signal
• This post-injection insulin spike is physiological, brief, and does not alter fasting insulin levels measured hours later
• It is the mechanism by which healthy users maintain normal fasting glucose despite the GH pulse

Comparison benchmarks:

• MK-677 (25 mg/day, 2-year RCT): fasting insulin rose meaningfully with compensatory hyperinsulinemia
• Tesamorelin (2 mg/day daily GHRH analog, 52 weeks, n=806): no significant fasting insulin or HOMA-IR change

Baseline: Fasting glucose and fasting insulin are sufficient. HOMA-IR can be calculated from these two values: (fasting insulin in mIU/L x fasting glucose in mmol/L) / 22.5. A value below 2.0 is normal; 2.0 to 2.9 is borderline; 3.0 or above is insulin resistant.

During use:

• Fasting insulin and calculated HOMA-IR every 6 months on a long-term protocol
• Increase to quarterly if stacking with AAS, MK-677, or exogenous GH
• If HOMA-IR rises above 2.0 from a previously normal baseline on CJC-1295 no-DAC alone, investigate other drivers before attributing to the peptide

Testing timing: Draw fasting insulin at least 4 to 6 hours after the most recent injection to avoid the acute post-injection insulin peak confounding the fasting measurement.

Optimising insulin sensitivity on a GH peptide protocol:

• Combine peptide use with resistance training and cardiovascular exercise; both independently improve insulin sensitivity and offset any GH-mediated metabolic load
• High dietary fibre (30 to 40 g/day) and low glycaemic index carbohydrates support insulin sensitivity
• Berberine 500 mg twice daily with meals is a conservative adjunct if any HOMA-IR drift is detected

If HOMA-IR rises above 2.5 on a CJC-1295 no-DAC protocol:

• First audit for independent insulin resistance drivers: increased body fat, sleep deprivation, AAS co-use, caloric surplus, thyroid dysfunction
• If no independent driver is found and timing correlates with peptide introduction, consider reducing injection frequency from 2x to 1x daily
• Switching to ipamorelin alone (removing the GHRH component) may reduce total GH pulse amplitude and is a viable dose-reduction strategy

Long-term considerations:

• No cumulative HOMA-IR deterioration is expected based on GHRH-class clinical data
• Metformin is not routinely indicated for CJC-1295 no-DAC users and is reserved for users who have independent pre-diabetes or type 2 diabetes